Looking for new treatments: Meditech and LEI team up
Wednesday, 22 May, 2002
Meditech Research and the Lion's Eye Institute (LEI) have signed a licence agreement allowing LEI to use patents owned by Meditech in developing products for the prevention and treatment of eye diseases.
"Meditech has a series of patents and the Lion's Eye Institute needed to access those patents to continue research into sub-retinal neovascularisation (SRNV)," said Meditech's CEO Chris Carter.
The patents relate to the use of hyaluronic acid (HA) as a means to carry DNA into cells, explained Dr Tracey Brown, Director of Scientific Operations at Meditech.
The agreement provides LEI with exclusive worldwide rights to use HA for any ocular gene therapy treatments they might develop.
Meditech has previously funded research at LEI for the use of HA in gene therapy to treat blindness due to SRNV. SRNV affects approximately 11 million people in developed countries and occurs primarily as a result of other diseases like diabetic retinopathy.
"LEI are leaders in the field of SRNV," said Carter.
Further commercialisation of the technology would probably involve partnership with a third party, according to LEI. The agreement provides for LEI to sublicence the patents.
Meditech and LEI will share any benefits arising from the agreement.
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
Portable point-of-care test detects four common STIs in under an hour
Australian researchers have developed a portable point-of-care test that detects four common...
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
